Failure to Obtain Informed Consent for Psychotropic Medications
Summary
The facility failed to ensure residents and/or their representatives were informed in advance of the care to be furnished by the physician or other provider, including the risks, benefits, side effects, and treatment alternatives related to psychotropic medications. Clinical record review showed that for 5 of 5 residents reviewed for psychotropic consent, there was no evidence of signed consent forms or documentation that the required discussions occurred before psychotropic medications were started or increased. Resident #3 had diagnoses including Alzheimer’s disease and anxiety disorder, with severe cognitive impairment noted on MDS review. The resident was prescribed multiple psychotropic medications, including lorazepam, mirtazapine, trazodone, haloperidol oral concentrate, and ABH gel. The record did not show that the resident’s representative was informed in advance of new psychotropic medications or dosage increases, and it did not show discussion of risks, benefits, side effects, or treatment alternatives. No signed psychotropic consent form was found in the record. Resident #9 had Alzheimer’s disease and major depressive disorder with psychotic features and severe cognitive impairment. The resident received trazodone and quetiapine. The record did not show advance notification to the representative about new psychotropic medications or dosage increases, nor documentation of risks, benefits, side effects, or alternatives. The resident’s representative told the surveyor that consent had never been requested, that they usually found out after the fact, and that they had never signed a psychotropic consent form or discussed the medications, side effects, risks, benefits, or alternative treatments. The representative also stated they were unaware the resident was receiving trazodone. Resident #26 had dementia and depression with severe cognitive impairment, and was prescribed Effexor XR and lorazepam intensol. Resident #46 had depression and anxiety disorder, with intact cognition, and was prescribed alprazolam, buspirone, and sertraline. Resident #64 had intellectual disabilities and major depressive disorder, with moderately impaired cognition, and was prescribed buspirone, duloxetine, multiple trazodone orders, Seroquel, and divalproex sodium. For each of these residents, the record failed to show advance informed consent, documentation of risks and benefits, side effects, or treatment alternatives, and signed psychotropic consent forms were not found. Resident #46 stated during interview that the facility did not discuss alternative treatments, side effects, or risks/benefits before starting new psychotropic medications. Resident #64’s representative stated they had never been asked to provide consent and had not been told about side effects, risks, benefits, or alternative treatment methods before psychotropic medications were started.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.